Abstract
Dilated cardiomyopathy (DCM), an incurable disease of the cardiomyocyte terminating in systolic heart failure (HFrEF), is prevalent, causes hospitalization and is associated with increased mortality. Despite evidence of immune activation in DCM, anti-inflammatory interventions so far did not prove to alter the course of this disease. Here we show that myeloperoxidase (MPO), the principal heme peroxidase expressed by polymorphonuclear neutrophils (PMN) and monocytes, critically contributes to HFrEF in DCM.
Muscle LIM protein (MLP) deficient mice, which spontaneously develop DCM, display increased circulating PMN counts and augmented levels of vessel-immobilized MPO. Genetic ablation and pharmacological inhibition of MPO resulted in enhanced nitric oxide (NO) bioavailability of systemic conductance and resistance vessels, and subsequently restoration of systolic left ventricular (LV) function, whereas infusion of MPO worsened systolic LV function. When patients diagnosed for DCM were treated with an orally available MPO inhibitor, systolic LV function increased, natriuretic peptides declined, and functional status improved.
Impairment of endothelial NO bioavailability by release of leukocyte-derived MPO evolves as a disease-aggravating mechanism in DCM. MPO inhibition profoundly improved ventricular function by lowering systemic vascular resistance and thus holds promise as a novel and complementary treatment strategy for patients with DCM.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
EudraCT-No. 2020-002788-80
Funding Statement
This work was supported by the Deutsche Forschungsgemeinschaft [GRK 2407 (360043781) to S.G. and D.M., SFB TRR259 (397484323; project A04 to H.W. and S.B.; project A05 to N.G.; project B05 to M.A.; project B06 to S.R.) Grant No. 236177352 CRC1116 (236177352 projects B06, B09) to M.K. and N.G., RU1678/3 3 to V.R., MO 3438/2 1 to M.M.]; the Center for Molecular Medicine Cologne [Baldus B02]; and the Cologne Fortune Program [344/2019 to S.B. (Simon Braumann), 363/2020 to F.S.N., 358/2021 to A.H.]. The clinical phase 2 pilot study was an investigator initiated trial, funded by AstraZeneca (Wedel, Germany).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The local Ethics Committee of the Medical Faculty of the University of Cologne gave ethical approval for this work (No. 19-1612-AMG-ff). The study is registered as EudraCT-No. 2020-002788-80
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data supporting the findings of this study are available from the corresponding author upon request.
